NRXP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NRXP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NRX Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2024 was $-2.31 Mil. NRX Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, NRX Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.
As of today, NRX Pharmaceuticals's current FCF Yield % is -29.51%.
The historical rank and industry rank for NRX Pharmaceuticals's FCF Margin % or its related term are showing as below:
The historical data trend for NRX Pharmaceuticals's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NRX Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
FCF Margin % | - | - | - | - |
NRX Pharmaceuticals Quarterly Data | ||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
FCF Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, NRX Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where NRX Pharmaceuticals's FCF Margin % falls into.
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
NRX Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
FCF Margin | = | Free Cash Flow (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | -21.66 | / | 0 | |
= | % |
NRX Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2024 is calculated as
FCF Margin | = | Free Cash Flow (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | -2.306 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of NRX Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jonathan C Javitt | director, 10 percent owner, officer: Chief Scientist | 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801 |
Richard Clavano Narido | officer: Interim CFO | 12 HANSEN CT, MORAGA CA 94556 |
Aaron Gorovitz | director | 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801 |
Chaim Hurvitz | director | C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL, HAMELECH BLVD, AMOT HAMISHPAT BLDG., TEL AVIV L3 64733 |
Voorhees Seth Van | officer: Chief Financial Officer | 12 HARVEY DRIVE, SHORT HILLS NJ 07078 |
Stephen H Willard | director, officer: Chief Executive Officer | 1201 ORANGE STREET, SUITE 600, WILMINGTON DE 19801 |
Daniel C. Javitt | 10 percent owner | 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801 |
Patrick John Flynn | director | 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801 |
Ira S Strassberg | officer: Chief Financial Officer | C/O CONTINENTAL BUILDING PRODUCTS, 12950 WORLDGATE DRIVE, HERNDON VA 20170 |
Robert Besthof | officer: Chief Comm. & Patient Officer | 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801 |
Alessandra Daigneault | officer: General Counsel & Secretary | 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801 |
Herbert Raymond Mcmaster | director | C/O ZOOM VIDEO COMMUNICATIONS, INC., 55 ALMADEN BOULEVARD, 6TH FLOOR, SAN JOSE CA 95113 |
William Fricker | officer: CFO & Treasurer | 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Big Rock Partners Sponsor, Llc | 10 percent owner | 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483 |
Richard Ackerman | director, 10 percent owner, officer: President & CEO | 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483 |
From GuruFocus
By PRNewswire • 12-30-2024
By PRNewswire • 09-30-2024
By PRNewswire • 11-13-2024
By PRNewswire • 02-06-2025
By PRNewswire • 11-07-2024
By PRNewswire • 08-26-2024
By PRNewswire • 02-03-2025
By PRNewswire • 10-03-2024
By GuruFocus Research • 08-15-2024
By GuruFocus Research • 08-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.